miR-143-5p suppresses breast cancer progression by targeting the HIF-1α-related GLUT1 pathway

JIA XU1*, XI LI2*, PURONG ZHANG1, JIE LUO1, EXIAN MOU1 and SHIWEI LIU1

1Department of Breast Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China; 2Department of Plastic Surgery, Chengdu First People's Hospital, Chengdu, Sichuan 610041, P.R. China

Received August 21, 2021; Accepted November 22, 2021

DOI: 10.3892/ol.2022.13268

Correspondence to: Dr Shiwei Liu, Department of Breast Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 55, Section 4, South Renmin Road, Wuhou, Chengdu, Sichuan 610041, P.R. China
E-mail: shiweilsc@163.com

*Contributed equally

Key words: breast cancer, microRNA-143-5p, hypoxia-inducible factor-1α, glucose transporter 1, migration

Abstract. Breast cancer (BC) is a commonly identified life-threatening type of cancer and a major cause of death among women worldwide. Several microRNAs (miRs), including miR-143-5p, have been reported to be vital for regulating hallmarks of cancer; however, the effect of miR-143-5p on BC requires further exploration. The present study performed bioinformatics analysis on GSE42072 and GSE41922 datasets from the National Center for Biotechnology Information Gene Expression Omnibus (GEO) database to identify miR-143-5p expression patterns. Furthermore, miR-143-5p expression was detected in BC cell lines and tissues via reverse transcription-quantitative PCR. Post-transfection with miR-143-5p mimics, Cell Counting Kit-8, colony formation and Transwell assays were performed to explore the effects of miR-143-5p on BC cell proliferation, colony formation, and migration. The association of miR-143-5p with the hypoxia-inducible factor-1α (HIF-1α)-related GLUT1 pathway was explored via western blotting, immunofluorescence and dual-luciferase reporter assay. The present study detected high expression of miR-143-5p in BC tissue of the GSE42072 and serum of the GSE41922 datasets by GEO chip analysis. Additionally, the expression levels of miR-143-5p were decreased in BC tissues compared with those in adjacent healthy tissues, and low miR-143-5p expression was associated with a poorer prognosis and shorter survival time in patients with BC.

In conclusion, miR-143-5p mimics suppressed BC cell proliferation, colony formation, migration. Furthermore, miR-143-5p targeted the HIF-1α-related GLUT1 pathway, and inhibited HIF-1α and GLUT1 expression. Additionally, HIF-1α agonists reversed the miR-143-5p-induced inhibition during tumorigensis. In conclusion, miR-143-5p exhibited low expression in BC tissues, and suppressed BC cell proliferation, colony formation, migration. Moreover, the antitumor effects of miR-143-5p targeted the HIF-1α-related GLUT1 pathway.

Introduction

Globally, breast cancer (BC) is currently the most diagnosed type of malignant cancer in women (1,2). BC has an incidence rate of 25% of all types of cancer and is responsible for 16% of cancer-related deaths of adult women worldwide (2,3). According to global cancer statistics, BC causes an estimated 410,000 deaths annually (4). Despite the progress made in BC detection and treatment processes, 5-45% of patients exhibit tumor recurrence after resection (5-7). A previous study revealed that BC invasion and metastasis into adjacent tissues and lymph nodes, rather than the primary tumor, are the main cause of death (8). Therefore, identifying suitable biomarkers and therapeutic targets related to BC metastases may improve treatment and regulation strategies.

MicroRNAs (miRNAs/miRs) are single-stranded noncoding RNA molecules, 18-25 nucleotides in length, which regulate ~30% of the expression of protein-coding genes through binding to the 3'-untranslated region (3'-UTR) of mRNA (9,10). miRNAs are involved in tumorigenesis, and are associated with numerous biological processes in cancer, such as proliferation, metastasis and drug resistance (11-13). Several miRNAs or miRNA families have been reported to act as oncogenes or tumor suppressor genes, and are vital regulating elements for BC hallmarks (14-16). For example, Troschel et al (17) demonstrated that miR-142-3p could decrease BC tumorigenic features and radioreistance by regulating β-catenin. Soheilyfar et al (18) reported that miR-143 was capable of suppressing metastasis and invasion in BC.

There have been various investigations regarding the mechanisms leading to the aberrant miRNA expression state within BC, and numerous miRNAs have been suggested to be BC biomarkers that can be used to predict diagnosis [i.e.,
miR-21-5p (19), miR-146b-5p (20) and miR-129 (21)], progression [i.e., miR-22 (22) and miR-330 (23)] and treatment results [i.e., miR-21 (24) and miR-629-3p (25)] via multiple signaling pathways. Therefore, systematic examination of important miRNAs in BC, and clarification of the function and mechanistic nature of these miRNAs could provide a basis for the diagnosis and treatment of BC.

miR-143-5p is located in the 5q32 chromosomal region, and has been reported to be decreased within human cancer tissues; notably, it is related to the progression and prognosis of numerous types of cancer, such as gallbladder cancer (26), lung adenocarcinoma (27), pancreatic cancer (28) and gastric cancer (29). Hypoxia-inducible factor-1α (HIF-1α) is a downstream miR-143-5p-targeted gene, which is under negative regulation via miR-143-5p within cancer (26,29,30). HIF-1α facilitates the metabolic transition to aerobic glycolysis by increasing the glycolytic protein glucose transporter 1 (GLUT1), which is independently associated with cancer metabolism and poor patient outcome (31). However, whether HIF-1α-mediated GLUT1 signaling is an underlying mechanism related to miR-143-5p requires further analysis. Therefore, the present study hypothesized that miR-143-5p inhibits the occurrence and development of BC, and that HIF-1α-mediated GLUT1 signaling is involved in the process of miR-143-5p playing an anti-BC role. The study aimed to examine the expression and biological importance of miR-143-5p in BC. Meanwhile, the potential mechanism of miR-143-5p was explored.

Materials and methods

Collection of GEO data. The BC microarray data were extracted from the GSE42072 and GSE41922 datasets in the GEO database (www.ncbi.nlm.nih.gov/geo), which is a public functional genomics information base for microarray gene expression datasets. The GSE42072 dataset contained miRNA expression data from 28 BC samples and 20 matched non-cancer tissue samples from the same BC cases based on the GPL15018 platform (32). The GSE41922 dataset contained miRNA expression data from 32 pre-operative serum samples from patients with BC and 22 healthy volunteer serum samples based on the GPL16224 platform (32). The R language ‘limma’ package (R version 4.1.2; https://www.r-project.org/) was used for analyzing miRNAs with differential expression based on the P<0.001 and |logFC|>2 thresholds. In addition, the data were used to generate a heatmap using OmicShare online platform (https://www.omicshare.com/).

Patients and samples. In the pre-experiment, the two groups (BC tissue and normal tissue) were designed to use for estimating sample size, CA153, as a diagnostic marker for BC in clinical work (33), has been used as a standard to estimate the required sample size. After obtaining the mean and standard deviation of CA153 expression levels in BC tissue and normal tissue, the \( \sigma^2 = \frac{\sum (n_1-1)S_1^2 + (n_2-1)S_2^2 + \ldots + (n_k-1)S_k^2}{(n_1 + n_2 + \ldots + n_k)} \) and \( n = \frac{Z_{1-\alpha}^2 + Z_{1-\beta}^2\sigma^2(1 + 1/k)}{\varepsilon^2} \) were used to calculate the minimum sample size. It was revealed that 40 samples would be sufficient for RNA and protein extraction; therefore, 40 BC samples and matched adjacent healthy tissue samples were obtained from patients diagnosed with BC undergoing surgery at the Sichuan Cancer Hospital & Institute (Chengdu, China) between January 2018 and December 2019. After surgical resection, the fresh specimens were immediately stored in liquid nitrogen until they could undergo reverse transcription-quantitative PCR (RT-qPCR). The detailed patient characteristics are described in Table I. The Ethical Committee of the Sichuan Cancer Hospital & Institute approved all studies (approval no. 2020-8748) and patients provided written informed consent.

Cell culture and transfection. MCF10A normal human breast epithelial cells, and the human BC cell lines T47D, MCF-7, ZR-75-1, MDA-MB-468, SK-BR-3 and BT-549, were obtained from the American Type Culture Collection. The BC cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco; Thermo Fisher Scientific, Inc.), supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and 1% streptomycin-penicillin (Gibco; Thermo Fisher Scientific, Inc.) at 37°C in an atmosphere containing 5% CO₂.

MCF10A cells were cultured in DMEM-Nutrient Mixture F-12 supplemented with 10% FBS at 37°C in an incubator containing 5% CO₂.

BT-549 and MCF-7 cells were cultured in 6-well plates at a density of 5x10⁴ per well. When cell confluence reached 70-80% (after culturing for 24 h), the culture medium was subsequently removed. On the next day, 20 nmol miR-143-5p mimics and NC mimics were mixed with 5 µl Lipofectamine® 2000 in 500 µl OptiMEM (cat. no. 11668019; Invitrogen; Thermo Fisher Scientific, Inc.), incubated for 15 min with 37°C and then added to the culture medium. After 48 h, cells were harvested and subjected to the subsequent experiments. The miR-143-5p mimics and the NC mimics were obtained from Shanghai GenePharma Co., Ltd. The sequences were as follows: miR-143-5p mimics, 5'-GGUGCGAGUGCGCAU CUCUGGU-3' and NC mimics, 5'-UGAGAUCAAAGGAAUG AACCCU-3', respectively. The HIF-1α agonist fenbendazole-d3 (cat. no. HY-B0413S; MedChemExpress LLC; 10 µmol/l) was used to activate the HIF-1α-related GLUT1 pathway. Briefly, when the cells were transfected with miR-143-5p mimics, the 20 µM HIF-1α agonist was also added to the culture medium. After incubation at 37°C for 48 h, the cells were harvested and subjected to the following experiments.

Cell proliferation assay. The proliferation of BT-549 and MCF-7 cells was analyzed using the Cell Counting Kit-8 (CCK-8) assay. Transfected cells (1x10⁵/well) were cultured in a 96-well plate with five replicates at 37°C with regulated humidity. Subsequently, 11 µl CCK-8 reagent (C0037; Beyotime Institute of Biotechnology) was added into each well at different periods (24, 48, 72 and 96 h) after transfection at 37°C. Following 4 h of culture, spectrometric absorbance at 450 nm was measured at 0, 12, 24, 48 and 72 h using a microplate reader.

Colony formation assay. Post-transfection, MCF-7 and BT-549 cells were cultured for 24 h. Subsequently, cells were cultured in a 6-well plate (2.5x10⁴ cells/well) for an additional 10 days. After this, During the incubation, transfections were renewed every 2 days. The cells were then washed twice with phosphate-buffered saline (PBS) for 3 min, and the cell colonies were stained for 5 min with 0.5% crystal violet supplemented...
with 20% methanol at room temperature. Images were captured and colonies with >50 cells were selected and counted.

**Transwell assay.** Using Transwell chambers, the ability of BT-549 and MCF-7 cells to migrate was measured. Briefly, cells (9x10⁴) were suspended in serum-free culture medium in a 24-well plate and then seeded into the upper chamber of a Transwell system (pore size, 8 µm; BD Biosciences). A total of 800 µl complete medium with 10% FBS was added to the lower chamber. Cells were incubated for 24 h at 37˚C, followed by staining with 0.1% crystal violet for 30 min at room temperature. The cells migrating to the lower chamber were observed under an inverted microscope (Zeiss, CFM-500). Image Pro-Plus 6.0 software (Media Cybernetics) was used to assess migration.

**Western blot analysis.** Total protein was extracted from BT-549 and MCF-7 cells using radioimmunoprecipitation assay lysis buffer (Beijing ComWin Biotech Co.) containing a protease inhibitor mixture. The BCA protein assay kit (Beyotime Institute of Biotechnology) was applied for determining protein concentration. Subsequently, equal amounts of protein (10 µg) were separated on 10% gels using SDS-PAGE and proteins were transferred to a nitrocellulose membrane (Amersham; Cytiva). After blocking with the 5% normal goat serum for 1 h at room temperature, the membranes were then incubated with β-actin (catalog no. ab8226; 1:10,000; Abcam), HIF-1α (catalog no. ab179483; 1:10,000; Abcam) and GLUT1 (catalog no. ab115730; 1:10,000; Abcam) antibodies at 4˚C overnight, washed and further incubated with the goat anti-mouse IgG-HRP secondary antibodies (catalog no. BS12471; 1:5,000; Bioworld Technology, Inc.) for 1 h at room temperature. ECL (catalog no. P0018FS; Beyotime Institute of Biotechnology) was then used to visualize the blots and Alpha View software (version no. 3.2.2.0; ProteinSimple, Inc.) was used to analyze them. β-actin was used as a loading control.

**RT-qPCR.** TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc.) reagent was used to extract total cellular and tissue miRNA, followed by usage of the mirVana Isolation Kit (Ambion; Thermo Fisher Scientific, Inc.). RNA concentration was measured with a NanoDrop ND-2000 spectrophotometer (NanoDrop; Thermo Fisher Scientific, Inc.). After RT of miRNA to cDNA using the TaqMan MicroRNA Reverse Transcription tool (Applied Biosystems; Thermo Fisher Scientific, Inc.), the expression levels of miR-143-5p were assessed using the PrimeScript miRNA RT-PCR Kit (Takara Bio, Inc.). A total volume of 10 µl was used for qPCR with the following thermocycling conditions: 95˚C for 30 sec for initial denaturation, followed by 40 cycles of 95˚C for 5 sec and 60˚C for 30 sec. Expression was determined using the 2-ΔΔCq method (34). The primer sequences were as follows: miR-143-5p, forward 5'-GGT GCA GTG CTG CAT CT'-3', reverse 5'-CTCAACTGGTGTCTGGGA-3'; and U6, forward, 5'-GCCAGCAGCACAATATCTAAAT-3', reverse 5'-CGTTTACAATTGGTGCAT-3'.

**Immunofluorescence assay.** BT-549 and MCF-7 cells (1x10⁴ cells) were added to culture dishes and then fixed with 4% paraformaldehyde for 20 min at room temperature. After

---

**Dual-luciferase reporter assay.** To determine whether HIF-1α was a target gene of hsa-miR-143-5p, TargetScan version 7.2 online software (www.targetscan.org) was used. The HIF-1α 3'-UTR was synthesized and cloned into the pmirGLO plasmid (Shanghai GenePharma Co., Ltd.). Cells were transfected with 0.1 µg reporter plasmid pmirGLO containing wild type (WT) or mutated (MUT) HIF-1α, and 0.4 µg NC mimics or miR-143-5p mimics using Lipofectamine 2000 transfection reagent (cat. no. 11668019; Invitrogen; Thermo Fisher Scientific, Inc.). After 48 h of transfection, luciferase activity was measured using a Dual-Luciferase Reporter Assay System (Promega Corporation). Firefly luciferase activity was normalized to Renilla luciferase activity, and the relative luciferase activity is presented as a ratio of firefly luciferase intensity to Renilla luciferase intensity.

**Table I. Clinicopathological characteristics of the patients and miR-143-5p expression in breast cancer.**

| Characteristic | Low (n=20) | High (n=20) | P-value |
|---------------|-----------|------------|---------|
| Age, years    | 0.723     |            |         |
| <55           | 29        | 15         | 14      |
| ≥55           | 11        | 5          | 6       |
| Menopause     | 0.748     |            |         |
| Premenopausal | 24        | 13         | 11      |
| Postmenopausal| 16        | 7          | 9       |
| Tumor size, cm| 0.029     |            |         |
| <2            | 26        | 9          | 17      |
| 2-5           | 10        | 8          | 2       |
| ≥5            | 4         | 3          | 1       |
| N stage       | 0.022     |            |         |
| N0            | 24        | 8          | 16      |
| N1-3          | 16        | 12         | 4       |
| M stage       | 0.025     |            |         |
| M0            | 22        | 7          | 15      |
| M1            | 18        | 13         | 5       |
| ER status     | 0.523     |            |         |
| Negative      | 23        | 13         | 10      |
| Positive      | 17        | 7          | 10      |
| PR status     | 0.527     |            |         |
| Negative      | 21        | 12         | 9       |
| Positive      | 19        | 8          | 11      |
| Her-2 status  | 0.741     |            |         |
| Negative      | 26        | 14         | 12      |
| Positive      | 14        | 6          | 8       |
| Ki67, %       | 0.341     |            |         |
| <14           | 22        | 9          | 13      |
| ≥14           | 18        | 11         | 7       |

ER, estrogen receptor; Her-2, human epidermal growth factor receptor; PR, progesterone receptor.
incubating with 10% goat serum (catalog no. C0265; Beyotime Institute of Biotechnology) for 1 h at room temperature and 0.3% hydrogen peroxide for 30 min at room temperature, BT-549 and MCF-7 cells were incubated with primary antibodies against HIF-1α (catalog no. ab179483; 1:500; Abcam) and GLUT1 (catalog no. ab115730; 1:500; Abcam) antibodies overnight at 4˚C. Cells were then washed three times with PBS plus 1% Tween 20, followed by a 45-min incubation with Alexa Fluor 488-labeled goat anti-rabbit IgG(H+L) (catalog no. C0265; Beyotime Institute of Biotechnology) and Alexa Fluor 555-labeled donkey anti-mouse IgG(H+L) (catalog no. A0460; Beyotime Institute of Biotechnology) at room temperature. The cell nuclei were subsequently stained with DAPI (Wuhan Boster Biological Technology, Ltd.) for 3 min at room temperature. The positive cells were observed under an inverted fluorescence microscope (Zeiss; YKDZ-80). Image Pro-Plus 6.0 software (Media Cybernetics, Inc.) was used to count the number of positive cells.

RNA transcriptome sequencing. To explore the target gene of miR-143-5p, transcriptome sequencing analysis was performed in BC cells transfected with NC mimics or miR-143-5p mimics. Since miR-143-5p had similar biological effects on BT-549 and MCF-7 cells, one of the two cell lines was randomly selected for RNA sequencing. MCF-7 was used for RNA transcriptome sequencing. Briefly, a Small RNA Sample
Prep Kit (catalog no. RS-200-0048; Illumina, Inc.) was used to construct miRNA libraries. A total of 3 ng RNA per sample was used as input material for the RNA sample preparations. In brief, mRNA was purified from total RNA using poly-T oligo-attached magnetic beads. Fragmentation was performed using divalent cations under elevated temperature in NEBNext First Strand Synthesis Reaction Buffer (5X). First-strand cDNA was synthesized using random hexamer primers and M-MuLV Reverse Transcriptase (catalog no. SO142; Thermo Fisher Scientific, Inc.). Second strand cDNA synthesis was subsequently performed using DNA Polymerase RNase H. Remaining overhangs were converted into blunt ends using exonuclease/polymerase activities. After adenylation of the 3' ends of the DNA fragments, the NEBNext Adaptor with a hairpin loop structure was ligated to prepare for hybridization. In order to select cDNA fragments of preferentially 150-200 bp in length, the library fragments were purified with the AMPure XP system. Next, 3 µl USER Enzyme (New England Biolabs, Inc.) was used with size-selected, adaptor-ligated cDNA at 37°C for 15 min, followed by 5 min at 95°C before PCR. PCR was performed using Phusion High-Fidelity DNA polymerase (catalog no. F630S; Thermo Fisher Scientific, Inc.), Universal PCR primers (catalog no. 48190011; Thermo Fisher Scientific, Inc.) and Index (X) Primer [catalog no. 12611ES02; Yeasen Biotechnology (Shanghai) Co., Ltd.]. Finally, the PCR products were purified (AMPure XP system), and the library quality was assessed on the Agilent Bioanalyzer 2100 system. The clustering of the index-coded samples was performed on a cBot Cluster Generation System using TruSeq PE Cluster Kit v3-cBot-HS (catalog no. FC-401-3002; Illumina, Inc.), according to the manufacturer's instructions. After cluster generation, the library preparations were sequenced on an Illumina HiSeq 2000 platform and paired-end reads were generated. Differentially expressed mRNAs were analyzed by Limma packages in R version 4.1.2 software (https://www.r-project.org/).

Enrichment analysis of differential gene pathways. The R language ‘limma’ package was used to analyze mRNA with differential expression based on the P<0.001 and |logFC|>2 thresholds. Subsequently, the pathway enrichment analysis was performed using OmicShare online platform (https://www.omicshare.com/) based on the Kyoto Encyclopedia of Genes and Genomes (KEGG). Subsequently, protein interaction network diagrams were constructed and visualized with Cytoscape 3.7.2 software (http://cytoscape.org/).

Figure 2. Overexpression of miR-143-5p suppresses tumorigenesis of breast cancer cells in vitro. (A) miR-143-5p mimics transfection increased miR-143-5p expression. (B and C) Overexpression of miR-143-5p suppressed cell proliferation, as determined using the Cell Counting Kit-8 assay. (D and E) Increased miR-143-5p expression restrained colony-forming ability. (F) Cell migration (original magnification, x200). (G) miR-143-5p overexpression suppressed cell migration, as measured through Transwell assays. Data are expressed as the mean ± SD. *P<0.05. miR, microRNA; NC, negative control.
**Results**

**GEO chip expression analysis of miR-143-5p.** After analysis of the GEO chip-based screening standards, i.e., logFC>2 and P<0.001, 40 differentially expressed miRNAs were identified between 28 BC tissues and 20 adjacent tissues from patients with BC in the GSE42072 dataset. miR-143-5p expression was increased within the GSE42072-derived BC samples compared with in the matched non-cancerous samples (P<0.001; Fig. 1A).
In addition, there were 29 differentially expressed miRNAs between 32 BC pre-operative serum samples and 22 volunteer serum samples in the GSE41922 dataset. miR-143-5p expression was higher in BC pre-operative serum compared with that in volunteer serum (P<0.001; Fig. 1B).

**Association between miR-143-5p expression and clinicopathological features.** BC and matched non-cancerous tissue samples were collected from 40 patients with BC; it was revealed that compared with those in paired adjacent tissues, the expression levels of miR-143-5p were significantly decreased in BC tissues (P<0.05; Fig. 1C). Kaplan-Meier survival analysis revealed that the survival rate of patients with high miR143-5p expression (split according to mean miR-143-5p expression levels) was higher than that in patients with lower expression levels of miR-143-5p (P<0.05; Fig. 1D and E). As shown in Table I, miR-143-5p expression was revealed to be associated with tumor size (P<0.05), N stage (P<0.05) and M stage (P<0.05), but not age (P>0.05), menopause (P>0.05), progesterone receptor status (P>0.05),...
human epidermal growth factor receptor status (P>0.05) or Ki67 levels (P>0.05). Moreover, miR-143-5p expression levels were significantly decreased in various BC cell lines compared with those in human common breast epithelial cells (P<0.05; Fig. 1F).

Overexpression of miR-143-5p is capable of suppressing tumorigenesis of BC cells. Since miR-143-5p expression levels were decreased in various BC cell lines, two cell lines were randomly selected to explore the biological role of miR-143-5p. Finally, miRNA mimics were used to upregulate the expression of miR-143-5p in BT-549 and MCF-7 cells. Post-transfection with miR-143-5p mimics, the expression levels of miR-143-5p were significantly increased compared with in cells transfected with NC mimics (Fig. 2A). Subsequently, the role of miR-145-5p in cell proliferation was determined by CCK-8 assay; notably, overexpression of miR-143-5p reduced the proliferative potential of BT-549 (P<0.05; Fig. 2B) and
MCF-7 (P<0.05; Fig. 2C) cells. When compared with the NC mimics group, overexpression of miR-143-5p significantly decreased the colony-forming capacity of BC cells (P<0.05; Fig. 2D and E). Moreover, as determined using the Transwell assay, overexpression of miR-143-5p suppressed the migration of BC cells (P<0.05; Fig. 2F and G).

**miR-143-5p targets the HIF-1α-related GLUT1 pathway.**

To study the detailed mechanism by which miR-143-5p inhibited the tumorigenesis of BC cells, differentially expressed genes were analyzed using the R language ‘limma’ package. The results showed that 34 differentially expressed genes were identified in BC cells transfected with miR-143-5p mimics (Fig. 3A and B). Subsequently, the pathway enrichment analysis of differentially expressed genes was carried out, and the HIF-1α-related pathway was identified (Fig. 3C). The PPI network of the differentially expressed genes is shown in Fig. 3D, which suggests that HIF-1α acts on GLUT1.

Figure 6. Inhibitory effect of miR-143-5p mimics on the tumorigenesis of BC cells are reversed by the HIF-1α agonist. (A-C) HIF-1α and GLUT1 protein expression levels were upregulated following treatment with the HIF-1α agonist. (D and E) Treatment with the HIF-1α agonist promoted cell proliferation, as shown by Cell Counting Kit-8 assay. (F) Cell immunofluorescence images (original magnification, x200). (G) Treatment with the HIF-1α agonist accelerated colony formation ability. (H and I) Treatment with the HIF-1α agonist facilitated the migration of cells, as indicated by Transwell assay. Data are expressed as the mean ± SD. *P<0.05 and #P<0.05. GLUT1, glucose transporter 1; HIF-1α, hypoxia-inducible factor-1α; miR, microRNA; NC, negative control.

To predict whether HIF-1α is a potential target gene of miR-143-5p, TargetScan 7.2 was used; it was revealed that miR-143-5p targets HIF-1α (Fig. 4A). According to the dual-luciferase reporter assay, miR-143-5p significantly decreased luciferase activity when cells were co-transfected with the reporter containing WT HIF-1α 3’-UTR compared with the reporter containing MUT HIF-1α 3’-UTR, which further indicated that miR-143-5p can target HIF-1α (P<0.05; Fig. 4B and C). After transfection with the miR-143-5p mimics, the protein expression levels of HIF-1α and GLUT1 were decreased in BT-549 (P<0.05, Fig. 4D and E) and MCF-7 cells (P<0.05; Fig. 4D and F). There was a significant inverse correlation between miR-143-5p and HIF-1α protein expression (P<0.05; Fig. 4G and J), and between miR-143-5p and
GLUT1 protein expression (P<0.05; Fig. 4H and K). There was a positive correlation between HIF-1α and GLUT1 protein expression in BT-549 (P<0.05; Fig. 4I) and MCF-7 cells (P<0.05; Fig. 4L).

In the immunofluorescence assay, green fluorescence indicated that HIF-1α (P<0.05) and GLUT1 (P<0.05) were significantly lower in the miR-143-5p mimics group compared with in the NC mimics group (Fig. 5A, B, F and G). Additionally, there was a negative correlation between miR-143-5p expression and GLUT1 (P<0.05; Fig. 5C and H), and between miR-143-5p expression and GLUT1 (Fig. 5D and I). Moreover, HIF-1α fluorescence expression was positively correlated with that of GLUT1 in BT-549 (P<0.05; Fig. 5E) and MCF-7 (P<0.05; Fig. 5J) cells. miR-143-5p suppresses tumorigenesis of BC cells via the HIF-1α-related GLUT1 pathway. To explore the role of miR-143-5p in suppressing BC cell carcinogenesis via the HIF-1α-related GLUT1 pathway, HIF-1α agonist fenbendazole-d3 was used to activate the HIF-1α-related GLUT1 pathway. Notably, the protein expression levels of HIF-1α and GLUT1 were elevated by fenbendazole-d3 in BT-549 (P<0.05; Fig. 6A and B) and MCF-7 cells (P<0.05; Fig. 6A and C). In addition, the inhibiting influence exerted by miR-143-5p on proliferation (P<0.05; Fig. 6D and E), colony-forming capacity (P<0.05; Fig. 6F and G), and migration (P<0.05; Fig. 6H and I) was reversed by the HIF-1α agonist.

Discussion

Increasing evidence has shown that miRNAs function as oncogenes or anti-oncogenes, and are involved in all types of important physiological processes in cancer initiation, progression, treatment and drug resistance (35-38). According to the results of the present study, miR-143-5p expression was decreased within BC cells and tissues, and was associated with the adverse progression of the tumor. Functionally, miR-143-5p overexpression induced by transfection with miR-143-5p mimics suppressed BC cell proliferation, migration and colony formation, as observed in BT-549 and MCF-7 cells. Mechanistically, HIF-1α was identified as a direct target gene of miR-4732-5p, and overexpression of miR-143-5p decreased the expression levels of HIF-1α and GLUT1. Furthermore, miR-143-5p-induced inhibition of proliferation, colony-forming capacity, and migration was reversed following treatment with a HIF-1α agonist. All of these data indicated the involvement of miR-143-5p during BC development and suggested it could suppress BC tumorigenesis via the HIF-1α-related GLUT1 pathway.

As a tumor suppressor, miR-143-5p has been reported to modulate various genes associated with the numerous elements of cancer progression and carcinogenesis (26,27,39). He et al (26) reported that miR-143-5p deletion was related to an advanced TNM stage, increased tumor size and poor survival in gallbladder carcinoma. In the current study, through bioinformatics analysis of datasets from the National Center for Biotechnology Information GEO database, it was revealed that miR-143-5p was downregulated in BC tissues compared with in adjacent healthy tissues in the GSE42072 dataset, thus suggesting that miR-143-5p may participate in BC biological processes. Furthermore, analysis of the GSE41922 dataset indicated that the expression levels of miR-143-5p in BC pre-operative serum were lower than those in serum from volunteers, which indicated that there may be potential diagnostic value in the use of miR-143-5p for BC.

To further explore miR-143-5p expression and its association with BC tumorigenesis and development, 40 BC and matched non-cancerous tissue samples were included in the present study; it was revealed that miR-143-5p expression was decreased in BC samples compared with that in matched non-cancerous tissue samples. Additionally, a lower level of miR-143-5p expression was associated with poor prognosis, including tumor size, N stage and M stage. A Kaplan Meier survival analysis revealed that the survival rate of patients with high miR-143-5p expression was markedly higher than that in patients with low miR-143-5p expression. Toda et al (40) performed RNA sequencing and also revealed that miR143-5p was downregulated in 20 BC clinical tissue specimens. García-Vazquez et al (41) verified the differential miR-143-5p expression among 17 cases with triple-negative BC in the presence or absence of a pathological complete response, and discovered that miR143-5p expression was related to longer disease-free survival.

To identify the role of miR-143-5p in cancer, the expression levels of miR-143-5p in the BC cell lines MCF-7, T47D, SK-BR-3, ZR-75-1, BT-549 and MDA-MB-468 were analyzed, and miR-143-5p mimics were used to overexpress miR-143-5p in BC cell lines. It was revealed that miR-143-5p expression was markedly decreased within the diverse types of BC cells compared with in breast epithelial cells. When miR-143-5p was overexpressed in MCF-7 and BT-549 cells, BC proliferation, migration and colony formation were inhibited. These findings indicated that miR-143-5p was capable of suppressing the tumorigenesis of BC cells; notably, previous studies revealed that miR-143-5p suppressed the proliferation, growth and invasion of gallbladder carcinoma (26), lung adenocarcinoma (27), gastric carcinoma (29) and colon carcinoma (42). These findings suggested that miR-143-5p may function as a tumor suppressor miRNA that participates in the pathogenesis and biological process of BC. The results of the present study may assist in understanding the exact mechanism underlying the effects of miR-143-5p on BC development at the molecular level.

HIF-1α is a vital element for resisting oxidative stress, and is critical to proliferation, angiogenesis, energy metabolism and oxygen homeostasis (43-45). HIF-1α may also enhance aggressive phenotypes of cancer cells via various intracellular signal transduction channels (44,46-48). GLUT1 is regulated by the transcription factor HIF-1α (49), and is a major controller of glycolytic flux in cells (50). It was previously revealed that the HIF-1α-associated GLUT1 pathway was associated with the pathogenesis of human papillomavirus-related lung carcinoma and the chemoresistance of acute myeloid leukemia (51,52). According to the present results, miR-143-5p may target the HIF-1α-related GLUT1 pathway, and overexpression of miR-143-5p was shown to decrease the expression levels of HIF-1α and GLUT1. Furthermore, the inhibitory effect of miR-143-5p on proliferation, colony-forming capacity and migration was reversed following treatment with a
HIF-1α agonist. These findings indicated that miR-143-5p may suppresses tumorigenesis of BC cells via HIF-1α-related GLUT1.

Cancer cells consume a greater amount of glucose for obtaining energy through glycolysis, a phenomenon also referred to as the Warburg effect (53). Activation of HIF-1α enhances glycolysis, and attenuates oxidative phosphorylation and the citric acid cycle (54). Previous studies have shown that mammalian cell oncogenic transformation is associated with numerous metabolic changes, particularly an increased rate of glucose transport. The glucose transporter GLUT1 can be stimulated by HIF-1α under hypoxic conditions by binding to cis-acting sites in the GLUT1 gene 5′ flanking region (55,56). Wang et al (57) revealed that HIF-1α was capable of suppressing transcription of GLUT1 under hypoxic conditions in human glioblastoma cells. As indicated by these research conclusions of the present study, miR-143-5p may inhibit the progression of BC by targeting the HIF-1α-related GLUT1 pathway.

In conclusion, the present study revealed that miR-143-5p was downregulated in BC tissues, which was associated with numerous metabolic changes, particularly an increased rate of glucose transport. The glucose transporter GLUT1 can be stimulated by HIF-1α under hypoxic conditions by binding to cis-acting sites in the GLUT1 gene 5′ flanking region (55,56). Wang et al (57) revealed that HIF-1α was capable of suppressing transcription of GLUT1 under hypoxic conditions in human glioblastoma cells. As indicated by these research conclusions of the present study, miR-143-5p may inhibit the progression of BC by targeting the HIF-1α-related GLUT1 pathway.

Acknowledgements
Not applicable.

Funding
This work was supported by the Scientific and Technological Project in Sichuan Province (grant no. 20YYJC1690).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. The microarray data are available in Array Express (accession no. E-MTAB-11160).

Authors' contributions
JX and XL participated in study design, and conducted experiments, analysis, manuscript drafting and revision. PZ, JL and EM participated in the study design, data interpretation and manuscript revision. EM and SL participated in the experiments and manuscript revision. JX and SL confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The Ethical Committee of the Sichuan Cancer Hospital and Institute approved all studies (approval no. 2020-8748) and patients provided written informed consent.

Patient consent for participation
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Harbeck N and Gnant M: Breast cancer. Lancet 389: 1134-1150, 2017.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
3. Smith RA, Calefﬁf M, Albert US, Chen TH, Dwyer SW, Franchesch D and Nystrøm L; Global Summit Early Detection and Access to Care Panel: Breast cancer in limited-resource countries: Early detection and access to care. Breast J 12 (Suppl 1): S16-S26, 2006.
4. DeSantis C, Siegel R, Bandi P and Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin 61: 409-418, 2011.
5. Lee MC and Jagsi R: Postmastectomy radiation therapy: Indications and controversies. Surg Clin North Am 87: 511-526, xi, 2007.
6. Danish Breast Cancer Cooperative Group, Nielsen HM, Overgaard M, Grau C, Jensen AR and Overgaard J: Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish breast cancer cooperative group DBCG 82 b and c randomized studies. J Clin Oncol 24; 2268-2275, 2006.
7. Ragaz J, Olivotto IA, Spinnelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K et al: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 97: 116-126, 2005.
8. Weigelt B, Peterse JL and van't Veer LJ: Breast cancer metastasis: Markers and models. Nat Rev Cancer 5: 591-602, 2005.
9. Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell 136: 215-233, 2009.
10. Bach DH, Lee SK and Sood AK: Circular RNAs in cancer. Mol Ther Nucleic Acids 16: 118-129, 2019.
11. Gandellini P, Doldi V and Zaffaroni N: microRNAs as players and signals in the metastatic cascade: Implications for the development of novel anti-metastatic therapies. Semin Cancer Biol 44: 132-140, 2017.
12. Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med 20: 460-469, 2014.
13. Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16: 203-222, 2017.
14. Bertoli G, Cava C and Castiglia I: MicroRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics 5: 1122-1143, 2015.
15. Liu Q, Peng F and Chen J: The role of exosomal MicroRNAs in the tumor microenvironment of breast cancer. Int J Mol Sci 20: 3884, 2019.
16. Aksiaf A, Ahmad ST, Arjumand W and Zargar MA: MicroRNAs in breast cancer: Diagnostic and therapeutic potential. Methods Mol Biol 1699: 23-43, 2018.
17. Troschel FM, Böhly N, Borrmann K, Braun T, Schwickert A, Kiesel L, Eich HT, Götte M and Greve B: miR-142-3p attenuates breast cancer stem cell characteristics and decreases radiosensitivity in vitro. Tumour Biol 40: 1010428318791887, 2018.
18. Soheilyfar S, Velashjerdi Z, Sayed Hajizadeh Y, Fathi Maroufi N, Amini Z, Khorrami A, Haj Azimian S, Isazadeh A, Taelehsorkh S and Taelehsorkh N: In vivo and in vitro impact of miR-31 and miR-143 on the suppression of metastasis and invasion in breast cancer. J BUON 23: 1290-1296, 2018.
19. Chen C, Liu X, Chen C, Chen Q, Dong Y and Hou B: Clinical significance of let-7a-5p and miR-21-5p in patients with breast cancer. Ann Clin Lab Sci 49: 302-308, 2019.
35. Li X, Zeng Z, Wang J, Wu Y, Chen W, Zheng L, Xi T, Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta CT) method. Methods 25: 402-408, 2001.

36. Xi L, Zeng Z, Wang J, Wu Y, Chen W, Zheng L, Xi T, Wang A and Lu Y: MicroRNA-9 and breast cancer. Biomed Pharmacother 122: 109687, 2020.

37. Zhao W, Geng D, Li S, Chen Z and Sun M: LncRNA HTAIR increases cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGAA2 axis in breast cancer. Cancer Med 7: 842-855, 2018.

38. Zhao H, Xu X and Guan H: CircACAP2 promotes breast cancer proliferation and metastasis by targeting mir-29a/b-3p-COL5A1 axis. Life Sci 244: 117179, 2020.

39. Ren S, Liu J, Feng Y, Li Z, He L, Li L, Cao X, Wang Z and Zhang Y: Knockdown of circDEND4C inhibits glycolysis, migration and invasion by up-regulating miR-200bc in breast cancer under hypoxia. J Exp Clin Cancer Res 38: 388, 2019.

40. Ardila HJ, Sanabria-Salas MC, Meneses X, Rios R, Huertas-Salgado A and Serrano ML: Circulating mir-141-3p, mir-143-3p and mir-200c-3p are differentially expressed in colorectal cancer and advanced adenomas. Mol Clin Oncol 11: 201-207, 2019.